Complementing the exciting and innovative scientific program, ISTH 2020 features supported symposia and product theaters showcasing the latest diagnostic and therapeutic innovations from our industry partners. See the full lineup below and plan to attend these sessions on Tuesday, July 14.


You can view the complete supported symposia product theater and overview including detailed programs here. 


See below for the session titles.



Tuesday, July 14, 8:45-10:00 EDT Supported Symposia

  • New Insights for Addressing Challenges in the Management of Patients with Cancer-Associated Thrombosis (Bayer AG)

  • The Evolution of FVIII to Meet Life-Long Patient Needs: New Data and Future Studies with Nuwiq (Octapharma)

  • Shaping Hemophilia Care Through Real-World Data: Stepping Closer to Reality (Novo Nordisk Healthcare AG)

  • From Science Fiction to Reality: A Journey of Evolving Scientific Innovation in Hemophilia B (Pfizer)

  • Update on Immune Thrombocytopenia: Clinical Perspectives (Grifols)

  • Challenges in the Management of VTE: New Evidence in the COVID-19 Era (Daiichi Sankyo Europe GmbH)

  • Current Perspectives on the Treatment of Primary Chronic ITP in Adults (COR2ED)

Tuesday, July 14, 10:15-11:30 EDT Supported Symposia

  • The Evolution of Safety in Hemophilia A: Adapting to an Ageing Population (F. Hoffman-La Roche Ltd.)

  • New Standards of Care: Treatment Across the Spectrum of Hemophilia B (CSL Behring)

  • Managing the Complexities of VWD- Clinical Experiences With Wilate® (Octapharma)

  • New Hopes and Opportunites for Hemophilia and Other Bleeding Disorders (Springer Healthcare IME)

  • Certainty Versus Myths - Increasing Certainty Around Individual Needs (Sobi)

  • From Protection to Bypass of Factor VIII in Inherited Bleeding Disorders: Insights and Therapeutic Options (LFB)

  • Building on a Decade of DOACs: Supporting Safety with Reversal (Boehringer Ingelheim)


Tuesday, July 14, 11:45-13:00 EDT Supported Symposia

  • Partnering for Progress: Driving Shared Decision Making in Haemophilia A Care (Roche)

  • Beyond Clinical Trials: Hemophilia A Care in the Real World (CSL Behring)

  • The Future of Hemophilia Treatment: Disrupting Expectations (Sanofi Genzyme)

  • Investigational AAV Gene Therapy for Hemophilia: Considerations for Potential Clinical Practice (Biomarin)

  • Key Questions in the New Hemophilia Era. Update on Concomitant Use of FVIII and Emicizumab (Grifols)



Tuesday, July 14, 13:15-14:00 EDT Product Theaters

  • Optimizing the Management of VTE with Rivaroxaban in Challenging Clinical Scenarios (Bayer AG)

  • Optimizing Hemophilia A Treatment in the Time of COViD-19 and Beyond (Bayer AG)

  • Advancing Standards of Care in VWD: Challenges, Diagnosis and Treatment (CSL Behring)

  • Empowering People with Haemophilia A Throughout Their Life (Sobi and Sanofi Genzyme)

  • Overcoming Uncertainty in Managing Haemophilia B (Sobi and Sanofi Genzyme)

  • COVID-19 Conundrums: Coagulopahty and Critical Care Implications for ROTEM(R) Testing (Instrumentation Laboratory)

  • Ceveron s100 - A Solution for Challenging Times in Haemostasis! (Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH)

Live Supported Symposia and Product Theater Presentations Will Be Available for On-Demand Viewing Shortly After Their Live Presentations



Supported On-Demand Only Symposia

  • Fit for Purpose: Personalized Prophylaxis for Joint Health and Beyond (Takeda)

  • Protein C Deficiencies and Their Impact in Critical Care (Takeda)

  • COVID-19 Patients and Viscoelastic Testing: What We Know So Far? (Haemonetics S.A.)

  • Spotlight on Women with Rare Bleeding Disorders (Novo Nordisk Healthcare AG)

  • State of the Art and Science in Prevention of VTE in Medical Patients (Sanofi)

  • The Immune System and AAV Gene Therapy: What Every Clinician Should Know (uniQure)

  • Optimizing Patient Care in Hemophilia A: A Critical Appraisal (Kedrion Biopharma)

  • VWD and TTP in Women: Taking a Patient-Centered Approach to Care (Takeda)

Supported On-Demand Only Product Theater Presentations

  • Urgent Warfarin Reversal for Fast and Sustained Action: A Case-Based Presentation (CSL Behring)

  • The Management of Severe Congenital Protein C Deficiency (Takeda)

  • Nearing 360° in Haemostasis Testing: Latest Developments From Sysmex (Sysmex)

  • Laboratory Updates on Specialized Hemostasis Testing (HYPHEN BioMed)

  • COVID-19 & Hemostasis: Laboratory and Clinical Updates (Instrumentation Laboratory)